TRDMT1
tRNA (cytosine(38)-C(5))-methyltransferase
Also known as: DNMT2, RNMT1, TRDMT_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O14717
- Gene
- TRDMT1
- Ensembl
- ENSG00000107614
- Chromosome
- 10
- Canonical length
- 391 aa
- Protein class
- Enzymes, Metabolic proteins, Predicted intracellular proteins
OverviewNCBI Gene
This gene encodes a protein responsible for the methylation of aspartic acid transfer RNA, specifically at the cytosine-38 residue in the anticodon loop. This enzyme also possesses residual DNA-(cytosine-C5) methyltransferase activity. While similar in sequence and structure to DNA cytosine methyltransferases, this gene is distinct and highly conserved in its function among taxa. [provided by RefSeq, Jun 2010]
Canonical amino-acid sequenceUniProt
391 residues, UniProt reviewed canonical sequence.
>O14717|TRDMT1
1 MEPLRVLELY SGVGGMHHAL RESCIPAQVV AAIDVNTVAN EVYKYNFPHT QLLAKTIEGI
61 TLEEFDRLSF DMILMSPPCQ PFTRIGRQGD MTDSRTNSFL HILDILPRLQ KLPKYILLEN
121 VKGFEVSSTR DLLIQTIENC GFQYQEFLLS PTSLGIPNSR LRYFLIAKLQ SEPLPFQAPG
181 QVLMEFPKIE SVHPQKYAMD VENKIQEKNV EPNISFDGSI QCSGKDAILF KLETAEEIHR
241 KNQQDSDLSV KMLKDFLEDD TDVNQYLLPP KSLLRYALLL DIVQPTCRRS VCFTKGYGSY
301 IEGTGSVLQT AEDVQVENIY KSLTNLSQEE QITKLLILKL RYFTPKEIAN LLGFPPEFGF
361 PEKITVKQRY RLLGNSLNVH VVAKLIKILY ELocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRDMT1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 5.4 nTPM
Expression across tissuesHPA
Tissue
- retina: 5.4 nTPM
- epididymis: 4.3 nTPM
- thyroid gland: 3.5 nTPM
- thymus: 3 nTPM
- cerebellum: 2.7 nTPM
- endometrium: 2.5 nTPM
Single-cell type
- ependymal cells: 215 nCPM
- müller glia: 114 nCPM
- pituicytes/fscs: 83 nCPM
- neutrophils: 76 nCPM
- rod photoreceptor cells: 63 nCPM
- pituitary stem cells: 59 nCPM
Immune cell
- plasmacytoid DC: 7 nTPM
- basophil: 5 nTPM
- naive CD4 T-cell: 4.9 nTPM
- MAIT T-cell: 4.2 nTPM
- memory CD4 T-cell: 3.8 nTPM
- naive B-cell: 3.6 nTPM
Brain region
- cerebellum: 13 nTPM
- pons: 10 nTPM
- basal ganglia: 8.3 nTPM
- medulla oblongata: 8.3 nTPM
- midbrain: 8 nTPM
- choroid plexus: 7.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.19
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.82
- DepMap mean gene effect
- 0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRDMT1 as an antibody target. Whether an autoantibody or antibody against TRDMT1 could matter depends on whether native TRDMT1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRDMT1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TRDMT1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...